1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., Romero D., Abdelmalek M.F., Anstee Q.M., Arab J.P., Arrese M., Bataller R., Beuers U., Boursier J., Bugianesi E., Byrne C.D., Castro Narro G.E., Chowdhury A., Cortez-Pinto H., Cryer D.R., Cusi K., El-Kassas M., Klein S., Eskridge W., Fan J., Gawrieh S., Guy C.D., Harrison S.A., Kim S.U., Koot B.G., Korenjak M., Kowdley K.V., Lacaille F., Loomba R., Mitchell-Thain R., Morgan T.R., Powell E.E., Roden M., RomeroGуmez M., Silva M., Singh S.P., Sookoian S.C., Spearman C.W., Tiniakos D., Valenti L., Vos M.B., Wong V.W., Xanthakos S., Yilmaz Y., Younossi Z., Hobbs A., Villota-Rivas M., Newsome P.N.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023; 78 (6): 1966-1986. DOI: 10.1097/HEP.0000000000000520 EDN: NKJIFL
2. Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А., Марченко Н.В., Прашнова М.К., Ивашкин В.Т. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2024; 34 (2): 35-44. DOI: 10.22416/1382-4376-2024-961 EDN: RVLEHF
3. Loomba R., Friedman S.L., Shulman G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021; 184 (10): 2537-2564. DOI: 10.1016/j.cell.2021.04.015 EDN: PMGQGX
4. Elsaid M.I., Bridges J.F.P., Li N., Rustgi V.K. Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro. Hep. Adv., 2022; 1 (3): 445-456. DOI: 10.1016/j.gastha.2022.02.002 EDN: VCPOAN
5. Hliwa A., Ramos-Molina B., Laski D., Mika A., Sledzinski T. The role of fatty acids in non-alcoholic fatty liver disease progression: an update. Int. J. Mol. Sci., 2021; 22 (13): 6900. DOI: 10.3390/ijms22136900 EDN: HHFGCP
6. Shroff H., VanWagner L.B. Cardiovascular disease in nonalcoholic steatohepatitis: screening and management. Curr. Hepatol. Rep., 2020; 19 (3): 315- 326. DOI: 10.1007/s11901-020-00530-0 EDN: TGIEUC
7. Dharmalingam M., Yamasandhi P.G. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J. Endocrinol. Metab., 2018; 22 (3): 421-428. DOI: 10.4103/ijem.IJEM_585_17
8. Tapper E.B., Fleming C., Rendon A., Fernandes J., Johansen P., Augusto M., Nair S. The burden of nonalcoholic steatohepatitis: a systematic review of epidemiology studies. Gastro. Hep. Adv., 2022; 1 (6): 1049-1087. DOI: 10.1016/j.gastha.2022.06.016 EDN: MFWWIL
9. Galatou E., Mourelatou E., Hatziantoniou S., Vizirianakis I.S. Nonalcoholic steatohepatitis (NASH) and atherosclerosis: explaining their pathophysiology, association and the role of incretin-based drugs. Antioxidants (Basel), 2022; 11 (6): 1060. DOI: 10.3390/antiox11061060 EDN: KYQHJY
10. Dağ H., İncirkuş F., Dikker O. Atherogenic Index of Plasma (AIP) and its association with fatty liver in obese adolescents. Children (Basel), 2023; 10 (4): 641. DOI: 10.3390/children10040641 EDN: VXWUFO
11. Avanaki F.A., Esteghamati A. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur. J. Med. Res., 2022; 27 (1): 112. DOI: 10.1186/s40001-022-00731-x EDN: ZXOPKL
12. Liu J., Zhou L., An Y., Wang Y., Wang G. The atherogenic index of plasma: A novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults. Front. Nutr., 2022; 9: 954219. DOI: 10.3389/fnut.2022.954219 EDN: VCEJDC
13. Balta S. Atherosclerosis and non-alcoholic fatty liver disease. Angiology, 2022; 73 (8): 701-711. DOI: 10.1177/00033197221091317 EDN: MGLKOZ
14. Wei S., Wang L., Evans P.C., Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov. Today, 2024; 29 (3): 103910. DOI: 10.1016/j.drudis.2024.103910
15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J. Hepatol., 2021; 75 (3): 659-689. DOI: 10.1016/j.jhep.2021.05.025 EDN: WHBZUS
16. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67 (1): 328-357. DOI: 10.1002/hep.29367 EDN: VDMEWM
17. Chen Z., Ma Y., Cai J., Sun M., Zeng L., Wu F., Zhang Y., Hu M. Serum biomarkers for liver fibrosis. Clin. Chim. Acta, 2022; 537: 16-25. DOI: 10.1016/j.cca.2022.09.022 EDN: QLLAUT
18. Long M.T., Gandhi S., Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism, 2020; 111: 154259. DOI: 10.1016/j.metabol.2020.154259 EDN: WKIYGF
19. Wong V.W.S., Adams L.A., de Lédinghen V., Wong G.L.H., Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat. Rev. Gastroenterol. Hepatol., 2018; 15: 461-478. DOI: 10.1038/s41575-018-0014-9
20. Yuan L., Terrrault N.A. PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver. Hepatobiliary Surg. Nutr., 2020; 9 (3): 353-356. DOI: 10.21037/hbsn.2019.10.35 EDN: NLCGCO
21. Ferraioli G., Monteiro L.B.S. Ultrasound-based techniques for the diagnosis of liver steatosis. World J. Gastroenterol., 2019; 25: 6053-6062. DOI: 10.3748/wjg.v25.i40.6053
22. Peng C., Stewart A.G., Woodman O.L., Ritchie R.H., Qin C.X. Non-alcoholic steatohepatitis: A review of its mechanism, models and medical treatments. Front. Pharmacol., 2020; 11: 1864. DOI: 10.3389/fphar.2020.603926 EDN: AUTJNK
23. Masarone M., Troisi J., Aglitti A., Torre P., Colucci A., Dallio M., Federico A., Balsano C., Persico M. Untargeted metabolomics as a diagnostic tool in NAFLD: Discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics, 2021; 17: 12. DOI: 10.1007/s11306-020-01756-1 EDN: TZPOAY
24. Tavares De Almeida I., Cortez-Pinto H., Fidalgo G., Rodrigues D., Camilo M.E. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr., 2002; 21: 219-223. DOI: 10.1054/clnu.2001.0529
25. Zhou Y., Orešič M., Leivonen M., Gopalacharyulu P., Hyysalo J., Arola J., Verrijken A., Francque S., Van Gaal L., Hyötyläinen T., Yki-Järvinen H. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin. Gastroenterol. Hepatol., 2016; 14 (10): 1463-1472.e6. DOI: 10.1016/j.cgh.2016.05.046
26. Feng R., Luo C., Li C., Du S., Okekunle A.P., Li Y., Chen Y., Zi T., Niu Y. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: A case-Control study. Lipids Health Dis., 2017; 16 (1): 165. DOI: 10.1186/s12944-017-0551-1 EDN: MOQAVQ
27. Puri P., Wiest M.M., Cheung O., Mirshahi F., Sargeant C., Min H.K., Contos M.J., Sterling R.K., Fuchs M., Zhou H., Watkins S.M., Sanyal A.J. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology, 2009; 50 (6): 1827-1838. DOI: 10.1002/hep.23229
28. Calder P.C. Functional roles of fatty acids and their effects on human health. JPEN J. Parenter. Enteral. Nutr., 2015; 39 (1 Suppl): 18S-32S. DOI: 10.1177/0148607115595980
29. Ивашкин В.Т., Маевская М.В., Жаркова М.С., Котовская Ю.В., Ткачева О.Н., Трошина Е.А., Шестакова М.В., Маев И.В., Бредер В.В., Гейвандова Н.И., Дощицин В.Л., Дудинская Е.Н., Ершова Е.В., Кодзоева Х.Б., Комшилова К.А., Корочанская Н.В., Майоров А.Ю., Мишина Е.Е., Надинская М.Ю., Никитин И.Г., Погосова Н.В., Тарзиманова А.И., Шамхалова М.Ш. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2022; 32 (4): 104- 140. DOI: 10.22416/1382-4376-2022-32-4-104-140 EDN: EXTLXM
30. Алкогольная болезнь печени (АБП) у взрослых. Клинические рекомендации. 2021-2022-2023. Режим доступа: http://disuria.ru/_ld/12/1219_kr21K-70MZ.pdf.
31. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома (второй пересмотр). Доктор.Ру, 2010; 3 (54): 15-18. EDN: MQFTHF
32. Munteanu M., Tiniakos D., Anstee Q., Charlotte F., Marchesini G., Bugianesi E., Trauner M., Romero Gomez M., Oliveira C., Day C., Dufour J.F., Bellentani S., Ngo Y., Traussnig S., Perazzo H., Deckmyn O., Bedossa P., Ratziu V., Poynard T.; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment. Pharmacol. Ther., 2016; 44 (8): 877-889. DOI: 10.1111/apt.13770
33. Кручинина М.В., Кручинин В.Н., Прудникова Я.И., Громов А.А., Шашков М.В., Соколова А.С. Исследование уровня жирных кислот мембран эритроцитов и сыворотки крови у пациентов с колоректальным раком г. Новосибирска. Успехи молекулярной онкологии, 2018; 5 (2): 50-61. DOI: 10.17650/2313-805X-2018-5-2-50-61 EDN: UUBZXO
34. Breiman L. Random forests. Machine Learning, 2001; 45: 5-32. :1010933404324. DOI: 10.1023/A EDN: ARROTH
35. Wang X., Cao Y., Fu Y., Guo G., Zhang X. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis., 2011; 10: 234. DOI: 10.1186/1476-511X-10-234 EDN: ECLZXN
36. Rada P., González-Rodríguez Á., García-Monzуn C., Valverde Á.M. Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver? Cell Death Dis., 2020; 11: 1-15. DOI: 10.1038/s41419-020-03003-w EDN: QOZDLR
37. Feng R., Luo C., Li C., Du S., Okekunle A.P., Li Y., Chen Y., Zi T., Niu Y. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: A case-Control study. Lipids Health Dis., 2017; 16 (1): 165. DOI: 10.1186/s12944-017-0551-1 EDN: MOQAVQ
38. Yamada K., Mizukoshi E., Sunagozaka H., Arai K., Yamashita T., Takeshita Y., Misu H., Takamura T., Kitamura S., Zen Y., Nakanuma Y., Honda M., Kaneko S. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int., 2015; 35 (2): 582-590. DOI: 10.1111/liv.12685
39. Yoo W., Gjuka D., Stevenson H.L., Song X., Shen H., Yoo S.Y., Wang J., Fallon M., Ioannou G.N., Harrison S.A., Beretta L. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS One, 2017; 12 (12): e0189965. DOI: 10.1371/journal.pone.0189965
40. Chen J.J., Fan Y., Boehning D. Regulation of dynamic protein s-acylation. Front. Mol. Biosci., 2021; 8: 656440. DOI: 10.3389/fmolb.2021.656440 EDN: RULHNQ
41. Powell E.E. A new treatment and updated clinical practice guidelines for MASLD. Nat. Rev. Gastroenterol. Hepatol., 2025; 22 (2): 88-89. DOI: 10.1038/s41575-024-01014-y EDN: VKOYYZ
42. Goldberg I.J., Ginsberg H.N. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology, 2006; 130: 1343- 1346. DOI: 10.1053/j.gastro.2006.02.040
43. Pfaffenbach K.T., Gentile C.L., Nivala A.M., Wang D., Wei Y., Pagliassotti M.J. Linking endoplasmic reticulum stress to cell death in hepatocytes: Roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. Am. J. Physiol. Endocrinol. Metab., 2010; 298: E1027-E1035. DOI: 10.1152/ajpendo.00642.2009
44. Chiappini F., Coilly A., Kadar H., Gual P., Tran A., Desterke C., Samuel D., Duclos-Vallée J.C., Touboul D., Bertrand-Michel J., Brunelle A., Guettier C., Le Naour F. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci. Rep., 2017; 7: 46658. DOI: 10.1038/srep46658 EDN: YDIMMX
45. Herrera-Marcos L.V., Arbones-Mainar J.M., Osada J. Lipoprotein lipidomics as a frontier in non-alcoholic fatty liver disease biomarker discovery. Int. J. Mol. Sci., 2024; 25 (15): 8285. DOI: 10.3390/ijms25158285 EDN: HMFBXR
46. Syed-Abdul M.M. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites, 2023; 14 (1): 12. DOI: 10.3390/metabo14010012 EDN: HKHMRD
47. Czumaj A., Śledziński T. Biological role of unsaturated fatty acid desaturases in health and disease. Nutrients, 2020; 12: 356. DOI: 10.3390/nu12020356 EDN: UKJVDW
